Torthaí cuardaigh - Arlene Naranjo

Beachtaigh na torthaí
  1. 1
    The ganglioside G<sub>D2</sub> as a circulating tumor biomarker for neuroblastoma

    The ganglioside G<sub>D2</sub> as a circulating tumor biomarker for neuroblastoma de réir Frank M. Balis, Christine M. Busch, Ami V. Desai, Emily Hibbitts, Arlene Naranjo, Rochelle Bagatell, Meredith S. Irwin, Elizabeth Fox

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future

    Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future de réir Wayne H. Liang, Sara M. Federico, Wendy B. London, Arlene Naranjo, Meredith S. Irwin, Samuel L. Volchenboum, Susan L. Cohn

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Children's Oncology Group's 2023 blueprint for research: Neuroblastoma

    Children's Oncology Group's 2023 blueprint for research: Neuroblastoma de réir Rochelle Bagatell, Steven G. DuBois, Arlene Naranjo, J. S. Van Belle, Kelly C. Goldsmith, Julie R. Park, Meredith S. Irwin

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials

    Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group earl... de réir Wendy B. London, Rochelle Bagatell, Brenda J. Weigel, Elizabeth Fox, Dongjing Guo, Collin Van Ryn, Arlene Naranjo, Julie R. Park

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2

    Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2 de réir James I. Geller, Peter F. Ehrlich, Nicholas G. Cost, Geetika Khanna, Elizabeth A. Mullen, Eric J. Gratias, Arlene Naranjo, Jeffrey S. Dome, Elizabeth J. Perlman

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children’s Oncology Group

    Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children’s Oncology Group de réir Sabah Servaes, Geetika Khanna, Arlene Naranjo, James I. Geller, Peter F. Ehrlich, Kenneth W. Gow, Elizabeth J. Perlman, Jeffrey S. Dome, Eric J. Gratias, Elizabeth A. Mullen

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study

    Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study de réir Julie R. Park, Jeffrey R. Scott, Clinton F. Stewart, Wendy B. London, Arlene Naranjo, Victor M. Santana, Peter J. Shaw, Susan L. Cohn, Katherine K. Matthay

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)

    Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG) de réir Navin Pinto, Arlene Naranjo, Emily Hibbitts, Susan G. Kreissman, Meaghan Granger, Meredith S. Irwin, Rochelle Bagatell, Wendy B. London, Emily Greengard, Julie R. Park, Steven G. DuBois

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Children’s Oncology Group

    Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Children’s Oncology Group de réir Geetika Khanna, Arlene Naranjo, Fredric A. Hoffer, Elizabeth A. Mullen, James I. Geller, Eric J. Gratias, Peter F. Ehrlich, Elizabeth J. Perlman, Nancy Rosen, Paul E. Grundy, Jeffrey S. Dome

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

    Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomis... de réir Pedro A. de Alarcón, Katherine K. Matthay, Wendy B. London, Arlene Naranjo, Sheena C. Tenney, Jessica A. Panzer, Michael D. Hogarty, Julie R. Park, John M. Maris, Susan L. Cohn

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Poverty and Targeted Immunotherapy: Survival in Children’s Oncology Group Clinical Trials for High-Risk Neuroblastoma

    Poverty and Targeted Immunotherapy: Survival in Children’s Oncology Group Clinical Trials for High-Risk Neuroblastoma de réir Kira Bona, Yimei Li, Lena E. Winestone, Kelly Getz, Yuan‐Shung Huang, Brian T. Fisher, Ami V. Desai, Troy Richardson, Matt Hall, Arlene Naranjo, Tara O. Henderson, Richard Aplenc, Rochelle Bagatell

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants

    A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants de réir Jed G. Nuchtern, Wendy B. London, Carol E. Barnewolt, Arlene Naranjo, Patrick McGrady, James D. Geiger, Lisa Diller, Mary Lou Schmidt, John M. Maris, Susan L. Cohn, Robert C. Shamberger

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group

    Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group de réir Gregory A. Yanik, Marguerite T. Parisi, Barry L. Shulkin, Arlene Naranjo, Susan G. Kreissman, Wendy B. London, Judith G. Villablanca, John M. Maris, Julie R. Park, Susan L. Cohn, Patrick McGrady, Katherine K. Matthay

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children’s Oncology Group Study ANBL0531

    Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children’s Oncology Group Study ANBL0531 de réir Clare J. Twist, Arlene Naranjo, Mary Lou Schmidt, Sheena C. Tenney, Susan L. Cohn, Holly J. Meany, Peter Mattei, E. Stanton Adkins, Hiroyuki Shimada, Wendy B. London, Julie R. Park, Katherine K. Matthay, John M. Maris

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project

    Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project de réir Elizabeth Sokol, Ami V. Desai, Mark A. Applebaum, Dominique Valteau‐Couanet, Julie R. Park, Andrew D.J. Pearson, Gudrun Schleiermacher, Meredith S. Irwin, Michael D. Hogarty, Arlene Naranjo, Samuel L. Volchenboum, Susan L. Cohn, Wendy B. London

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Children's Oncology Group's 2013 blueprint for research: Renal tumors

    Children's Oncology Group's 2013 blueprint for research: Renal tumors de réir Jeffrey S. Dome, Conrad V. Fernandez, Elizabeth A. Mullen, John A. Kalapurakal, James I. Geller, Vicki Huff, Eric J. Gratias, David Dix, Peter F. Ehrlich, Geetika Khanna, Marcio H. Malogolowkin, James R. Anderson, Arlene Naranjo, Elizabeth J. Perlman

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG

    Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG de réir Chizuko Okamatsu, Wendy B. London, Arlene Naranjo, Michael D. Hogarty, Julie M. Gastier‐Foster, A. Thomas Look, Michael P. LaQuaglia, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Robert C. Seeger, Tsutomu Saji, Hiroyuki Shimada

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1

    A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1 de réir Alix E. Seif, Arlene Naranjo, David L. Baker, Nancy Bunin, Morris Kletzel, C. Kretschmar, John M. Maris, Patrick McGrady, Daniel von Allmen, Susan L. Cohn, Wendy B. London, J R Park, Lisa Diller, Stephan A. Grupp

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

    Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group de réir Kevin Campbell, Julie M. Gastier‐Foster, Meegan Mann, Arlene Naranjo, Collin Van Ryn, Rochelle Bagatell, Katherine K. Matthay, Wendy B. London, Meredith S. Irwin, Hiroyuki Shimada, Meaghan Granger, Michael D. Hogarty, Julie R. Park, Steven G. DuBois

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma

    Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma de réir Puja J. Umaretiya, Arlene Naranjo, Fan F. Zhang, Julie R. Park, Brian Weiss, Meaghan Granger, Ami V. Desai, M. Fevzi Özkaynak, Alice L. Yu, Rahela Aziz‐Bose, Sandi L. Pruitt, Steven G. DuBois, Rochelle Bagatell, Kira Bona

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: